Share
Paul Jones
Halia Therapeutics, also known as The Genetic Resilience Company, has appointed Paul Jones as Chief Strategy Officer and GM, International Markets, marking a significant step in strengthening its global genomics leadership.
In this newly created role, Jones will drive the growth of GENMOR-AI, Halia’s proprietary artificial intelligence platform that identifies genetic modifiers of disease, advancing the company’s mission to develop first-in-class anti-inflammatory therapies.
His appointment further deepens Halia’s collaboration with the Department of Health – Abu Dhabi, which leverages the Emirati Genome dataset to uncover genetic resilience factors that protect individuals from disease.
With more than 30 years of experience in life sciences, genomics, digital health transformation, and precision medicine, Jones brings a wealth of expertise. Most recently, he served as CEO of the Omics Centre of Excellence at M42, where he led the Emirati Genome Program, one of the largest national genomics initiatives globally.
His prior leadership roles include Global Head of Population Genomics at Illumina and CEO of Genomics Enterprises at Genomics England, where he was instrumental in delivering the landmark 100,000 Genomes Project.
Jones’s appointment will also advance Halia’s APOE4 program in Alzheimer’s disease, which explores why certain individuals carrying high-risk genetic variants remain disease-free. By leveraging GENMOR-AI and population-scale genomic data, Halia aims to uncover resilience mechanisms that can guide novel therapies for neurodegeneration, metabolic disorders, cardiovascular disease, and cancer.
